The effect of ascorbic-acid (50817) on the induction of sister chromatid exchanges (SCEs) by cyclophosphamide (50180) (CPA) and mitomycin-C (50077) (MMC) was studied in bone marrow and spleen cells of mice under in-vivo and in-vivo/in-vitro conditions. Male CD-1-mice were given intraperitoneal injections of 40mg/kg CPA, 2.5mg/kg MMC or vehicle, followed immediately by injections of 0, 1.67, 3.34, or 6.68 grams per kilogram (g/kg) ascorbic-acid. Under in-vivo conditions, animals were pretreated with 5-bromo-2'- deoxyuridine (BrdUrd) and were administered colchicine prior to sacrifice. Under in-vivo/in-vitro conditions, animals were not pretreated with BrdUrd and colchicine was added to cells after incubation. Ascorbic-acid alone did not cause any significant change in number of SCEs. CPA or MMC alone caused about a seven fold increase in number of SCEs under both conditions. There was a dose related decrease in CPA and MMC induced SCEs with all doses of ascorbic-acid under in-vivo conditions. Under in-vivo/in-vitro conditions, there was a dose related decrease in CPA and MMC induced SCEs with doses of ascorbic-acid up to 3.34g/kg. However, in doses of 6.68g/kg, ascorbic-acid acted as a coinducer of SCEs with both CPA and MMC under in-vivo/in-vitro conditions. There were no changes in cell replication kinetics under in-vivo conditions; however, under in-vivo/in-vitro conditions, 6.68g/kg of ascorbic- acid along with CPA or MMC, caused significant cell cycle delay and toxicity. The authors conclude that CPA or MMC induced SCEs decrease with increasing concentrations of ascorbic-acid under in- vivo and in-vivo/in-vitro conditions. The paradoxical increase in SCEs at the highest dose of ascorbic-acid under in-vivo/in-vitro conditions remains unexplained. The authors postulate that ascorbic- acid has threshold levels at which it acts as an inhibitor or coinducer of SCE under culture conditions.
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.